Généthon appoints biopharma industry expert Frédéric Revah as Chief Executive
Généthon announced the appointment of Frédéric Revah PhD as Chief Executive. Frédéric Revah brings over 20 years' experience in the pharmaceutical and biotech industries and academic research to the job.
Immediately prior to joining Généthon in January 2010, Frédéric Revah had been Chief Executive Officer of the oncology start-up Sepal Pharma since 2008. Before that, he had served as Vice President, Drug Discovery, and Chief Scientific Officer Director at the NYSE Euronext-listed biotech company Cerep from 1999 to 2007 and Chief Executive Officer of its oncology subsidiary. At Cerep, Frédéric Revah had worldwide responsibility for the company's R&D platform (250 researchers and technicians) and took several molecules into the clinic. Prior to his time at Cerep, Frédéric Revah was Head of the Gene Therapy Department in the Central Nervous System and Neurochemistry Department at Rhône Poulenc Rorer (now sanofi-aventis) from 1992 to 1998. Frédéric started his career as an associate staff researcher at the Pasteur Institute (from 1990 to 1992). He obtained his doctorate at the Pasteur Institute/University of Paris V in 1991 and is a graduate (1985) of the elite Ecole Polytechnique engineering school.
Frédéric Revah has served as an advisor to several private- or public-sector organizations, including the French National Scientific Research Center's laboratory evaluation committee (2001-2004) and the Scientific Advisory Board at Edmond de Rothschild Investment Partners (until 2007).
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
